Le Lézard

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2…

Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that it has submitted a Biologics License ...
Le Lézard

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Summit Therapeutics Inc. today announced it has entered into a clinical trial collaboration with GSK plc ("GSK", LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific ...